IFN-α2 Autoantibody Screening and Functional Evaluation in Viral and Bacterial Infections
The Journal of Applied Laboratory Medicine · 2024
DOI: 10.1093/jalm/jfae080 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2024. Verfasst von Maaike Cockx und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Diagnostic Immunology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Autoantibodies, COVID-19, Bacterial Infections, SARS-CoV-2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
The presence of anti-interferon (IFN)-α2 autoantibodies is a strong indicator of severe disease course during viral infections and is observed in autoimmune diseases (e.g., myasthenia gravis). Detection of these autoantibodies during severe bacterial infections is understudied. Multiple anti-IFN-α2 autoantibody screening assays are available. However, the results do not always correlate with the neutralizing capacity of the autoantibodies.
Methods
Anti-IFN-α2 antibodies were measured by a Luminex-based assay in serum samples from individuals admitted to the intensive care unit infected with influenza (n = 38), invasive bacteria (n = 152), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (n = 52). Anti-IFN-α2 antibodies were also studied in individuals with myasthenia gravis (n = 22) and in healthy individuals (n = 37). Individuals testing positive by Luminex were subsequently tested by enzyme-linked immunosorbent assay (ELISA) and tested for nonspecific reactivity and neutralization.
Results
Three of 16 Luminex-positive samples had nonspecific reactivity, 11/16 were positive by ELISA, and 10/16 had neutralizing activity. Anti-IFN-α2 antibodies were found in individuals infected with SARS-CoV-2 (7/52), influenza (3/38), invasive bacteria [2/152, of which 1 was Legionella pneumophilia and was 1 Escherichia coli (E. coli) (out of 39 E. coli infections)], and in individuals with myasthenia gravis (2/22).
Conclusions
Anti-IFN-α2 autoantibodies were detected in viral infections, myasthenia gravis, and rarely in bacterial infections. ELISA and Luminex screening assays do not give similar results. Nonspecific reactivity and functional assays are necessary to validate the screening test result.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical and Diagnostic Immunology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
- Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
- Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
- Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
- Department of Neurosciences, Laboratory for Muscle Diseases and Neuropathies, KU Leuven, and Leuven Brain Institute, Leuven, Belgium.
- Laboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
ORCID-Profile: Maaike Cockx, Pieter Vermeersch, Kristl G Claeys
Zitieren
APA
Cockx, M., Steels, S., Michiels, B., Van Elslande, J., Vermeersch, P., Frans, G., Claeys, K. G., Desmet, S., De Munter, P., & Bossuyt, X. (2024). IFN-α2 Autoantibody Screening and Functional Evaluation in Viral and Bacterial Infections. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfae080
Vancouver
Cockx M, Steels S, Michiels B, Van Elslande J, Vermeersch P, Frans G, et al. IFN-α2 Autoantibody Screening and Functional Evaluation in Viral and Bacterial Infections. The Journal of Applied Laboratory Medicine. 2024. doi:10.1093/jalm/jfae080
BibTeX
@article{Cockx2024,
author = {Cockx, Maaike and Steels, Sophie and Michiels, Birthe and Van Elslande, Jan and Vermeersch, Pieter and Frans, Glynis and Claeys, Kristl G and Desmet, Stefanie and De Munter, Paul and Bossuyt, Xavier},
title = {IFN-α2 Autoantibody Screening and Functional Evaluation in Viral and Bacterial Infections},
journal = {The Journal of Applied Laboratory Medicine},
year = {2024},
doi = {10.1093/jalm/jfae080}
}
EUVIMED